Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine

Comparative Efficacy of Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine

This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.

Migraine is a chronic neurological disorder characterized by recurrent headaches, affecting millions globally. Peripheral nerve blocks such as Greater Occipital Nerve (GON) and Sphenopalatine Ganglion (SPG) blockade have emerged as promising non-pharmacologic treatments.

Inclusion Criteria:

• Adults aged 18-65 years.
• Both sexes.
• Diagnosed with episodic migraine per the International Classification of Headache Disorders, 3rd edition (ICHD-3).
• Failure to achieve adequate relief with at least one prophylactic migraine treatment.

Exclusion Criteria:

• Chronic migraine (≥15 headache days per month).
• History of nerve blocks within the last 6 months.
• Known allergy to anesthetic agents.
• Pregnancy or lactation.
• Active psychiatric conditions affecting compliance.